US-based Nuvation Bio Inc., a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Japan's Eisai Co., Ltd, a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, have announced an exclusive license and collaboration agreement that significantly expands the long-term global footprint of taletrectinib (marketed as IBTROZI® in the US and Japan).
Taletrectinib is a highly selective, next-generation oral treatment currently approved for patients living with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in the US, China and Japan.
Eisai will now have exclusive development, registration and commercialisation rights for taletrectinib for the treatment of ROS1+ NSCLC in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India.
Nuvation Bio will continue to lead global development and retain full US commercial rights, maintaining its strong focus on US launch activities and ongoing pivotal studies of taletrectinib across early- and late-stage ROS1+ NSCLC.
Under the terms of the exclusive license and collaboration agreement, Nuvation Bio will receive €50million (approx. $60 million) upfront and up to €145 million (approx. $170 million) in regulatory and commercial milestone payments, as well as double-digit tiered royalties up to the high-teens as a percentage of future net sales in the licensed territories.
Following the upfront payment, Nuvation Bio will receive the first milestone payment of €25 million (approx. $30 million) from this transaction upon achievement of EU regulatory approval (conditional or full) of taletrectinib.
